Compare CTXR & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTXR | ELUT |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 23.3M |
| IPO Year | N/A | 2020 |
| Metric | CTXR | ELUT |
|---|---|---|
| Price | $0.92 | $0.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.6M | 553.6K |
| Earning Date | 02-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $21,746,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $147.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.63 | $0.50 |
| 52 Week High | $4.43 | $3.80 |
| Indicator | CTXR | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 52.48 |
| Support Level | $0.76 | $0.60 |
| Resistance Level | $0.99 | $0.73 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 50.00 | 68.14 |
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.